Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
458.248189839
InChI
InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)
InChI Key
InChIKey=GXDALQBWZGODGZ-UHFFFAOYSA-N
IUPAC Name
1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine
Traditional IUPAC Name
astemizole
SMILES
COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
pKa (Strongest Basic)
8.75
Refractivity
135.64 m3·mol-1
Dược Lực Học :
Astemizole is a second generation H1-receptor antagonist. It does not significantly cross the blood brain barrier and therefore does not cause drowsiness or CNS depression at normal doses.
Cơ Chế Tác Dụng :
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Astemizole competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of astemizole to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier and preferentially binds at H1 receptors in the peripehery rather than within the brain, CNS depression is minimal. Astemizole may also act on H3-receptors, producing adverse effects.
Dược Động Học :
▧ Absorption :
Rapidly absorbed from the gastrointestinal tract.
▧ Protein binding :
96.7%
▧ Metabolism :
Almost completely metabolized in the liver and primarily excreted in the feces.
▧ Half Life :
1 day
Độc Tính :
LD50=2052mg/kg in mice
Chỉ Định :
Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
Tương Tác Thuốc :
-
Amprenavir
Increased risk of cardiotoxicity and arrhythmias
-
Aprepitant
Increased risk of cardiotoxicity and arrhythmias
-
Bepridil
Increased risk of cardiotoxicity and arrhythmias
-
Cimetidine
Increased risk of cardiotoxicity and arrhythmias
-
Cisapride
Increased risk of cardiotoxicity and arrhythmias
-
Clarithromycin
Increased risk of cardiotoxicity and arrhythmias
-
Delavirdine
Increased risk of cardiotoxicity and arrhythmias
-
Efavirenz
Increased risk of cardiotoxicity and arrhythmias
-
Erythromycin
Increased risk of cardiotoxicity and arrhythmias
-
Fluoxetine
Increased risk of cardiotoxicity and arrhythmias
-
Fluvoxamine
Increased risk of cardiotoxicity and arrhythmias
-
Fosamprenavir
Increased risk of cardiotoxicity and arrhythmias
-
Grepafloxacin
Increased risk of cardiotoxicity and arrhythmias
-
Indinavir
Increased risk of cardiotoxicity and arrhythmias
-
Itraconazole
Increased risk of cardiotoxicity and arrhythmias
-
Josamycin
Increased risk of cardiotoxicity and arrhythmias
-
Ketoconazole
Increased risk of cardiotoxicity and arrhythmias
-
Mesoridazine
Increased risk of cardiotoxicity and arrhythmias
-
Mibefradil
Increased risk of cardiotoxicity and arrhythmias
-
Nefazodone
Increased risk of cardiotoxicity and arrhythmias
-
Nelfinavir
Increased risk of cardiotoxicity and arrhythmias
-
Posaconazole
Contraindicated co-administration
-
Quinine
Increased risk of cardiotoxicity and arrhythmias
-
Quinupristin
This combination presents an increased risk of toxicity
-
Ritonavir
Increased risk of cardiotoxicity and arrhythmias
-
Saquinavir
Increased risk of cardiotoxicity and arrhythmias
-
Sparfloxacin
Increased risk of cardiotoxicity and arrhythmias
-
Telavancin
Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
-
Telithromycin
Increased risk of cardiotoxicity and arrhythmias
-
Thioridazine
Increased risk of cardiotoxicity and arrhythmias
-
Tipranavir
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated.
-
Troleandomycin
Increased risk of cardiotoxicity and arrhythmias
-
Voriconazole
Increased risk of cardiotoxicity and arrhythmias
Liều Lượng & Cách Dùng :
Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
-
Sản phẩm biệt dược : Acemiz
-
Sản phẩm biệt dược : Alerkin
-
Sản phẩm biệt dược : Astesen
-
Sản phẩm biệt dược : Hismanal
-
Sản phẩm biệt dược : Histalong
-
Sản phẩm biệt dược : Lergibrumizol
-
Sản phẩm biệt dược : Stemiz